U.S. FDA Approves the Labeling Update of Abilify Maintena® (Aripiprazole) for Extended-Release Injectable Suspension to Describe New Clinical Data for the Treatment of Acutely Relapsed Adults with Schizophrenia

Yahoo!Finance
December 6, 2014
U.S. FDA Approves the Labeling Update of Abilify Maintena® (Aripiprazole) for Extended-Release Injectable Suspension to Describe New Clinical Data for the Treatment of Acutely Relapsed Adults with Schizophrenia

Dr. John M. Kane, Chairman, Psychiatry, Zucker Hillside Hospital

Read this Story

Focus onHealth TV

Watch Focus onHealth, Northwell Health's TV show. It's the healthy way to stay informed!